| Metric | Value (₹ Cr) | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue | 1.8K | 6.5% | 7.3% |
| Total Income | 1.9K | 10.2% | 8.6% |
| Expenditure | 1.9K | 4.6% | 3.2% |
| PBT | -31.23 | 126.9% | 128.9% |
| Net Profit | 30.10 | 53.5% | 65.5% |
| OPM | 26.60% | 2.15pp | 4.69pp |
| NPM | 1.59% | 1.49pp | 2.63pp |
| EPS | 0.07 | 56.3% | 66.7% |
Detailed report is being prepared.
A test of momentum: can Reliance Power extend Q1's margin recovery?
Regulatory headwinds shadow a quarter that should deliver steady revenue with the street pricing in 140% upside from current levels.
The Setup: Recovery on Trial
The number that matters: Can Reliance Power sustain the margin recovery it showed in Q1 FY27, or will regulatory noise crimp execution? The company reported a 45% jump in consolidated PAT to ₹64.71 Cr in Q1, even as revenue grew just 3.75% YoY to ₹1,956.32 Cr. That margin pop—underpinned by improved EBITDA and cost control—is the foundation for Street sentiment. Q2 will test whether that's repeatable.
~₹1,950–₹2,000 Cr
In line with Q1 ₹1,956 Cr and prior-year Q2 at ₹1,974 Cr; commodity/dispatch mix stable
PAT ₹60–75 Cr
Q1 at ₹64.71 Cr +45% was inflated by one-time gains; normalization to ₹60–70 Cr range likely
₹44–45
From 48 analysts; Buy bias dominant (26 buy, 4 strong buy, 11 hold, 6 sell). Implies ₹18.8 → +140%
₹18.8 | RSI 49.9
Down 75% from ATH ₹76.49; above SMA20 ₹18.18 but below SMA50 ₹19.86 & SMA200 ₹24.21. Volume declining.
What the Street Says
Coverage is moderately thick, with TipRanks and regional research houses tracking the name actively. The bull case rests on: (i) stable commodity power revenues and improving despatch economics, (ii) margin expansion from cost discipline, and (iii) a deeply discounted valuation after the equity crash. The bear case cites regulatory exposure and the company's stated position that ED/CBI actions carry no expected operational impact—though the Street is watchful.
On Track? The Trajectory Test
Q1 FY27 signaled momentum: revenue +3.75% YoY, PAT +45% YoY. That margin lift was sharp and merits scrutiny—one-time gains (regulatory settlements, asset sales, forex) often inflate a quarter. If Q2 normalizes to ₹60–70 Cr PAT (vs. ₹64.71 Cr in Q1), that's still solid YoY growth and consistent with the Board's unverified near-term guidance. Management has been silent on full-year targets since the regulatory onslaught began. The baseline assumption is that commodity despatch remains stable and EBITDA holds steady around ₹600–625 Cr per quarter—achievable if no operational disruption flows from the ED/CBI actions.
Since Last Quarter: Regulatory Shock
Aug 6
Q1 FY27 Results: Revenue ₹1,956.32 Cr +3.75% YoY; PAT ₹64.71 Cr +45% YoY
Positive signal; margin momentum the headline
Aug 6
Monitoring Agency Report filed for preferential issue utilization (Q2 FY26)
Routine regulatory compliance
Aug 14
32nd AGM held; all resolutions passed unanimously; audited FY26 results adopted
Governance routine
Aug 17
CBI Pre-Cognizance Notice (PMLA): Reliance CleanGen subsidiary flagged in ₹715 Cr complaint
Regulatory friction; under contestation
Sep 7
CBI Chargesheet filed: Reliance Power named accused in Reliance Commercial Finance matter
Pending legal process; company denies wrongdoing
Sep 25
Director Resignation: Shri Sachin Mohapatra (Non-Exec, Non-Indep) resigns for personal reasons
Governance change; attributed to personal circumstances
Oct 1
CBI Chargesheet: Reliance Power named accused in Reliance Home Finance matter
Pending legal process; company statement pending
Oct 13
ED Seizure Order (FEMA): ₹20.32 Cr assets (shares in Sasan Power + bank balances) attached
Balance-sheet friction; company contests; no ops impact stated
Nov 5
Board Meeting Scheduled for Nov 12 to approve Q2 FY27 unaudited results
Result announcement imminent
The risk picture: The ED seizure (Oct 13) of ₹20.32 Cr is material but not catastrophic—the company holds ₹20+ Cr in typical quarterly liquid balances. Sasan Power, the subsidiary whose shares were seized, is a productive asset and the company is contesting the FEMA attachment. The CBI chargesheets (Sep 7, Oct 1) name Reliance Power as accused in legacy affiliate disputes (Reliance Commercial Finance, Reliance Home Finance)—these are distress-era liabilities, not current-quarter operating issues. Management's stated position is that no operational or financial impact is expected. The Street is monitoring for contagion, but the consensus remains that regulatory noise is containable and balance-sheet friction is priced into the valuation.
Ownership Snapshot
FII ownership has drifted down to 13.64% (from 14.13% in Q4 FY26), while DII remains steady at 2.79%. Promoter holding is rock-solid at 24.98% across quarters—no distress selling. The decline in foreign flows likely reflects broader emerging-market caution and sector concerns (power demand, coal prices, regulatory overhang), not company-specific deterioration.
Three Things to Watch on Result Day
1 · Margin sustain: Is Q2 PAT in the ₹60–75 Cr range?
Q1's +45% PAT growth was impressive. If Q2 normalizes to ₹60–70 Cr (still strong growth), the margin recovery story holds. If PAT drops below ₹55 Cr or misses guidance, expect a downside re-rate. Watch EBITDA and tax rate detail.
2 · Revenue trajectory: Is despatch/commodity mix holding?
Revenue should land near Q1 levels (~₹1,956 Cr, +3–4% YoY). A material miss signals dispatch headwinds or merchant capacity underutilization. A beat would suggest faster demand or better pricing.
3 · Regulatory commentary: Any update on ED/CBI contestation?
Management will likely reiterate 'no operational impact' on the CBI/FEMA cases. Watch the tone: Are they confident or defensive? Any hint of asset freezes or operational restrictions would reprrice risk. Also, watch for any disclosure of settlement timelines or financial provisions.
Reliance Power enters Q2 with a quarter of margin momentum but a year of regulatory friction. The Street is priced for recovery: a 140% target from current levels on the back of an analyst Buy consensus is bullish positioning. Revenue should hold steady in the ₹1,950–2,000 Cr range; the real question is whether the 45% PAT jump in Q1 is the new baseline or a one-time inflection. The ED seizure and CBI cases are real friction, but the company's track record of contesting such matters and the promoter's stable holding suggest balance-sheet discipline over operational shutdown. Expect a steady Q2 that either validates the Street's optimism or triggers a reassessment of regulatory tail risk. The stock's 75% slump from ATH has priced in a lot of pessimism; a clean result and no new regulatory bombshells could trigger re-rating upside into the consensus ₹44–45 range.